The past 12 months have exciting at Safeguard Scientifics. In December of 2010, partner companies Clarient and Avid Radiopharmaceuticals were both acquired by giants in…
Posted by
Last week our own Gary J. Kurtzman, MD, Senior Vice President and Managing Director in the Safeguard Life Sciences Group, participated on a panel at…
Posted by
This morning, we announced our second quarter 2011 financial results and reported on the exciting progress we’ve made this quarter. We deployed $45.8 million of…
Posted by
Earlier this afternoon, life sciences partner company Advanced BioHealing (ABH) announced it had signed a definitive agreement to be acquired by Shire plc (LSE: SHP,…
Posted by
This morning, we announced our fourth quarter and year-end 2010 financial results. In 2010, our aggregate partner company revenue was $403 million, up 54 percent…
Posted by
James A. Datin, Executive Vice President and Managing Director of Life Sciences Group at Safeguard Scientifics, discusses his thoughts on the opportunities in life sciences…
Posted by
While there are a wealth of opportunities to deploy capital in a variety of life sciences companies, the evolution and potential long-term impact of regenerative…
Posted by
After spending the better part of the past two weeks meeting with money managers in financial centers throughout the Midwest and Southeast, it seems to…
Posted by
Safeguard Scientifics’ strategy is to deploy capital in growth-stage companies in attractive sectors of the life sciences and technology industries. Within life sciences, we target…
Posted by
